In my opinion Edwards taking 3.4M shares at above market price to give us enough cash to get both FDA approval and CE mark would be ideal. This would give EW just under 19.9% of the business, I’d give them an option that allows them to keep the same percentage as the options are being converted. As part of this deal an agreed value could be placed on a takeover on achieving all endpoints and commercial registrations, as a minimum I would expect this to be $5B, in which case it would cost EW $4B as they would already have just under 20%.
This type of arrangement would also eliminate the need for the nasdaq listing in my view.
$66.32 price target - Evolution Capital initiation of coverage, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M | |||
| Open | High | Low | Value | Volume |
| $5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3500 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.27 | 200 | 1 |
View Market Depth
| Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |